Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Abbott Laboratories (ABT)

Abbott Laboratories (ABT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 199,993,312
  • Shares Outstanding, K 1,772,362
  • Annual Sales, $ 31,904 M
  • Annual Income, $ 3,687 M
  • 60-Month Beta 0.83
  • Price/Sales 6.25
  • Price/Cash Flow 22.64
  • Price/Book 6.33
Trade ABT with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate 1.36
  • Number of Estimates 9
  • High Estimate 1.40
  • Low Estimate 1.34
  • Prior Year 0.95
  • Growth Rate Est. (year over year) +43.16%

Price Performance

See More
Period Period Low Period High Performance
1-Month
107.26 +5.21%
on 01/04/21
113.54 -0.62%
on 01/21/21
+4.56 (+4.21%)
since 12/22/20
3-Month
103.13 +9.42%
on 10/30/20
115.14 -2.00%
on 11/06/20
+3.36 (+3.07%)
since 10/22/20
52-Week
61.61 +83.15%
on 03/23/20
115.14 -2.00%
on 11/06/20
+20.98 (+22.84%)
since 01/22/20

Most Recent Stories

More News
Diverticular Disease Market Professional Survey Report Industry: Key Trends, Challenges and Standardization to 2023

ABT : 112.84 (-0.10%)
ALPMF : 16.2500 (+1.58%)
SGYP : 0.03 (-52.00%)
VRX.TO : 30.80 (-3.33%)
The Latest: Shanghai locks down 2 major hospitals over cases

BEIJING — Shanghai has imposed lockdowns on two of China’s best-known hospitals after they were linked to new coronavirus cases.

PCRFY : 14.1000 (+2.47%)
PFE : 36.55 (+0.19%)
LLY : 206.14 (+1.87%)
ABT : 112.84 (-0.10%)
2020 Insights on the Worldwide Medical Devices & Diagnostics Industry to 2021 - Affects of COVID-19 on Companies Including Medtronic, Abbott Laboratories & GE Healthcare

The "The COVID Impact on Global Medical Devices & Diagnostics Markets: 2020 Review & 2021 Forecast" report has been added to ResearchAndMarkets.com's offering.

ABT : 112.84 (-0.10%)
MDT : 116.58 (-1.13%)
The U.S. is Still Struggling to Keep Up with Pandemic Testing

At the moment, the global number of pandemic cases is up to 95.9 million, with 2.05 million unfortunate ...

RYMDF : 0.2600 (unch)
LH : 228.90 (+0.20%)
ABT : 112.84 (-0.10%)
DGX : 124.46 (-0.58%)
CEMI : 6.31 (+1.77%)
RELA.CN : 0.335 (+3.08%)
Demand for COVID-19 Tests to Drive Abbott (ABT) Q4 Earnings

Within EPD, Abbott (ABT) is expected to have witnessed visible signs of rebound through Q4.

ABT : 112.84 (-0.10%)
THC : 50.74 (+1.38%)
ANTM : 314.09 (-2.37%)
TDOC : 263.00 (+7.13%)
Abbott Receives Expanded Medicare Reimbursement for First-Of-Its-Kind MitraClip™ Device

ABBOTT PARK, Ill., /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) revised its National Coverage Determination (NCD) to expand coverage...

ABT : 112.84 (-0.10%)
The Zacks Analyst Blog Highlights: Quest Diagnostics, Abbott, Becton, Dickinson and Co, Quidel and Hologic

The Zacks Analyst Blog Highlights: Quest Diagnostics, Abbott, Becton, Dickinson and Co, Quidel and Hologic

BDX : 258.75 (-1.20%)
DGX : 124.46 (-0.58%)
HOLX : 75.70 (-0.29%)
ABT : 112.84 (-0.10%)
QDEL : 233.61 (+6.92%)
Anticonvulsants Market Size, Share, Outlook, and Opportunity Analysis, 2018-2026

MENAFN19012021003520003262ID1101457649

ABT : 112.84 (-0.10%)
GSK : 38.36 (+1.54%)
NVS : 96.90 (+0.02%)
PFE : 36.55 (+0.19%)
SHPG : 179.20 (+4.10%)
TEVA : 12.55 (+4.85%)
VRX.TO : 30.80 (-3.33%)
Federal, Private Tie-Ups Boost COVID-19 Testing Volume

The Department of Health and Human Services (HHS) promises over $22 billion of funding.

BDX : 258.75 (-1.20%)
DGX : 124.46 (-0.58%)
HOLX : 75.70 (-0.29%)
ABT : 112.84 (-0.10%)
QDEL : 233.61 (+6.92%)
Anticonvulsants Market Size, Share, Outlook, and Opportunity Analysis, 2018-2026

MENAFN19012021003520003262ID1101457649

ABT : 112.84 (-0.10%)
GSK : 38.36 (+1.54%)
NVS : 96.90 (+0.02%)
PFE : 36.55 (+0.19%)
SHPG : 179.20 (+4.10%)
TEVA : 12.55 (+4.85%)
VRX.TO : 30.80 (-3.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. They have a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals.

See More

Key Turning Points

3rd Resistance Point 115.42
2nd Resistance Point 114.47
1st Resistance Point 113.65
Last Price 112.84
1st Support Level 111.88
2nd Support Level 110.93
3rd Support Level 110.11

See More

52-Week High 115.14
Last Price 112.84
Fibonacci 61.8% 94.69
Fibonacci 50% 88.38
Fibonacci 38.2% 82.06
52-Week Low 61.61

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar